PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today announced the installation of an EOS® imaging system at the Orthopaedic University Hospital Friedrichsheim in Frankfurt (OUHF), a leading German university orthopaedic healthcare provider. OUHF is the first academic institution in Germany to install EOS equipment.
The Orthopaedic University Hospital Friedrichsheim is ranked among the leading hospitals in Germany and has received numerous awards, including an award for orthopaedic excellence by AOK, the country’s largest health insurance fund. The current installation highlights the level of trust and credibility EOS has established among academic and private practitioners in the country.
Professor Meurer, Director at the University's Friedrichsheim Hospital and Head of the Department of Orthopedic Surgery said, “As a leading university hospital, we are committed to supplying our physicians with the technology required to deliver the best possible patient outcomes and the best medical research potential. Our decision to install an EOS system was guided by this commitment.”
Marie Meynadier, CEO of EOS imaging, said, “This EOS installation at Frankfurt, a leading German university hospital, is indicative of the trend of EOS adoption in the German market and throughout Europe. The Orthopaedic University Hospital Friedrichsheim’s decision to rely on EOS for 2D/3D orthopaedic imaging is an acknowledgement of the trust that has been established for EOS imaging with both private medicine and academic medical institutions.”
For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 1st half of 2014, on July 22, 2014 (after market).